Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
C4 Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -41.02%, a change of 23.09% year-over-year.
C4 Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -44.31%, a change of 8.61% year-over-year.
C4 Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -40.92%, a change of 7.84% year-over-year.
C4 Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -77.12%, a change of -33.65% year-over-year.
C4 Therapeutics, Inc. roe for fiscal 2025 was -40.92%, a change of 7.84% from fiscal 2024.
C4 Therapeutics, Inc. roe for fiscal 2024 was -48.76%, a change of 5.07% from fiscal 2023.
C4 Therapeutics, Inc. roe for fiscal 2023 was -53.83%, a change of -9.52% from fiscal 2022.
C4 Therapeutics, Inc. roe for fiscal 2022 was -44.32%, a change of -22.78% from fiscal 2021.